Status:

COMPLETED

A Study of Safety and the Local Anesthetic Effect of AG-920 Ophthalmic Solution in a Pediatric Population

Lead Sponsor:

American Genomics, LLC

Conditions:

Anesthesia, Local

Eligibility:

All Genders

Up to 10 years

Phase:

PHASE3

Brief Summary

A Phase 3, randomized, active-controlled, study in pediatric subjects. It is designed to evaluate the safety and anesthetic efficacy of one dose of AG-920 ophthalmic solution compared to Proparacaine ...

Detailed Description

A Phase 3, randomized, active-controlled, single-masked, parallel-group design study in pediatric subjects performed in the US. It is designed to evaluate the safety and anesthetic efficacy of one dos...

Eligibility Criteria

Inclusion

  • Pre-pubescent with no childbearing potential
  • Capable of undergoing an eye exam
  • Subject's legally appointed and authorized representative willing to sign and date an informed consent form (ICF) and, where appropriate, the subject willing to sign an assent form prior to any study-related procedures being performed.
  • Parent/legal guardian and subject are willing and able to follow instructions and can be present for the required study visits and Follow-up Phone Call for the duration of the study.
  • Have a healthy, normal cornea.

Exclusion

  • Have participated in an investigational study (drug or device) within the past 30 days.
  • Have a known contraindication to local anesthetics.
  • Children with known autism spectrum disorders or known to have heightened sensitivity.
  • Corneal pathology that would make the corneal sensitivity lower/higher or make the test hard to perform or interpret.
  • Have low visual acuity
  • Manifest nystagmus
  • Have had ocular surgery or general surgery within the past 45 days.
  • Have had an intravitreal injection in either eye within 14 days of randomization.
  • Have ocular surface disease.

Key Trial Info

Start Date :

April 6 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 27 2022

Estimated Enrollment :

61 Patients enrolled

Trial Details

Trial ID

NCT05325853

Start Date

April 6 2022

End Date

May 27 2022

Last Update

October 25 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

American Genomics Site 2

McAllen, Texas, United States, 78503